User login
The quadrivalent conjugate meningococcal vaccine Menveo is now licensed for use in children down to age 2 months, according to Novartis, the manufacturer.
Previously, Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) was licensed for children and adults aged 2-55 years. It was initially licensed in the United States in February 2010 for adolescents and adults aged 11-55 years, and the age was expanded down in January 2011. It is indicated for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis.
The approval was based on the results of three studies involving more than 8,700 infants in the United States, Australia, Canada, Latin America, and Taiwan, according to the statement from Novartis announcing the approval.
The quadrivalent conjugate meningococcal vaccine Menveo is now licensed for use in children down to age 2 months, according to Novartis, the manufacturer.
Previously, Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) was licensed for children and adults aged 2-55 years. It was initially licensed in the United States in February 2010 for adolescents and adults aged 11-55 years, and the age was expanded down in January 2011. It is indicated for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis.
The approval was based on the results of three studies involving more than 8,700 infants in the United States, Australia, Canada, Latin America, and Taiwan, according to the statement from Novartis announcing the approval.
The quadrivalent conjugate meningococcal vaccine Menveo is now licensed for use in children down to age 2 months, according to Novartis, the manufacturer.
Previously, Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) was licensed for children and adults aged 2-55 years. It was initially licensed in the United States in February 2010 for adolescents and adults aged 11-55 years, and the age was expanded down in January 2011. It is indicated for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis.
The approval was based on the results of three studies involving more than 8,700 infants in the United States, Australia, Canada, Latin America, and Taiwan, according to the statement from Novartis announcing the approval.
